טוען...
PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta(®)): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers
INTRODUCTION: PF-06881894 is a proposed biosimilar to pegfilgrastim (Neulasta(®)). This study evaluated the pharmacodynamic/pharmacokinetic (PD/PK) equivalence, immunogenicity, and safety of PF-06881894 vs pegfilgrastim reference products (US- and EU-Neulasta(®)) in healthy volunteers. METHODS: A ph...
שמור ב:
| הוצא לאור ב: | Adv Ther |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer Healthcare
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7467414/ https://ncbi.nlm.nih.gov/pubmed/32524499 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-020-01387-x |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|